Table 3.
Analysis of measles-specific immune responses to MMR vaccine by genetic ancestry, separated by cohort.
| Rochester cohort | San Diego cohort | U.S. cohort | Total | |||||
|---|---|---|---|---|---|---|---|---|
| African- American (n=40) |
Caucasian (n=942) |
African- American (n=164) |
Caucasian (n=718) |
African- American (n=113) |
Caucasian (n=895) |
African- American (n=317) |
Caucasian (n=2,555) |
|
| Neutralizing Ab titer, mIU/mLa | ||||||||
| Mean (SD)* |
1,886 (2,179) |
1,313 (1,263) |
2,257 (3,376) |
1,257 (1,486) |
1,856 (2,051) |
1,237 (2,088) |
2,065 (2,821) |
1,271 (1,652) |
| Median (IQR)† |
894 (449; 2,593) |
902 (435; 1,751) |
1,224 (552; 2,637) |
770 (372; 1,526) |
1,238 (672; 2,598) |
702 (334; 1,404) |
1,180 (550; 2,632) |
803 (383; 1,607) |
| Adjusted p-value |
0.703 | 7.1 × 10−8 | 2.41 × 10−6 | 1.41 × 10−11 | ||||
| IFN-γ ELISPOT response (SFU / 5×105 PBMCs)b | ||||||||
| Mean (SD)* |
49.5 (39.8) |
38.6 (39) |
18.7 (19.3) |
14 (18.2) |
24 (23.9) |
21 (28.2) |
24.4 (26) |
25.2 (31.4) |
| Median (IQR)† |
45 (21.3; 71.5) |
26 (8.33; 57) |
12.3 (6; 23.7) |
9.33 (3.75; 20.6) |
15.7 (8.58; 34.3) |
14.3 (7; 27.8) |
15 (7; 34.5) |
15 (6;32.7) |
| Adjusted p-value |
0.64 | 0.005 | 0.094 | 0.0013 | ||||
a
Neutralizing antibody titer (mIU/mL), measured by the plaque reduction microneutralization assays (PRMN);
b
IFN-γ ELISPOT spot forming units (SFU), measured per 2 × 105 PBMCs (mean of measles virus-specific response, measured in triplicate wells, minus the mean of unstimulated response, also measured in triplicate wells)
*
Standard Deviation
†
Interquartile Range